Steroid use linked to worse outcomes in Lyme disease-associated facial paralysis

September 06, 2016

(BOSTON) - Researchers from Massachusetts Eye and Ear/Harvard Medical School have found that patients who were prescribed corticosteroids as part of treatment for Lyme disease-associated facial paralysis had worse long-term outcomes of regaining facial function than those who were prescribed antibiotic therapy alone. Based on these findings, which were published online today in Laryngoscope, the researchers urge caution in prescribing corticosteroids to patients with acute Lyme disease-associated facial paralysis.

"While further study is needed to determine the effect of corticosteroids in the setting of acute Lyme disease-associated facial paralysis, this retrospective study demonstrated a clear association between their use and worse long-term facial outcomes", said lead author Nate Jowett, M.D., FRCSC, a facial plastic and reconstructive surgeon at Massachusetts Eye and Ear and an Instructor in Otolaryngology at Harvard Medical School. "Since corticosteroids are part of the standard of care for acute viral facial paralysis, it is not surprising that they were initially prescribed to roughly two-thirds of the patients with Lyme disease-associated facial paralysis in this study. Our findings underline the importance of differentiating patients with facial weakness due to Lyme disease -- for whom the standard of care is prompt antibiotic therapy -- from those with acute viral facial paralysis, such as Bell's palsy or varicella-zoster virus -- for whom the standard of care includes early treatment with corticosteroids and antivirals."

Lyme disease is the most common vector-borne human illness in the Northern hemisphere, with an estimated 300,000 Americans infected each year, and a confirmed incidence of 60 cases per 100,000 residents in New England each year. Facial paralysis, a temporary loss of the ability to move the facial muscles on one or both sides, is a common manifestation of the disease. While most patients will recover normal facial function over the weeks to months following the initial paralysis, some will develop cross-wiring of nerve cells as they regenerate resulting in permanent incoordination of facial movements known as synkinesis on the involved side of the face.

In the largest study of its kind, the researchers studied the long-term recovery (an average of 15 months) of 51 patients with Lyme disease-associated facial paralysis who sought follow-up care in the Facial Nerve Center at Mass. Eye and Ear. Patients were grouped into those who were previously treated with triple therapy (antibiotics, antivirals and corticosteroids), double therapy (antibiotics and corticosteroids), or antibiotics alone to determine whether differences in long-term facial function outcomes might exist between groups.

Using validated, standardized tests for measuring the outcomes of patients with facial paralysis, experts who were naïve to the treatment patients received studied video documentation of a standardized sequence of facial expressions for each patient. Comparison of facial function scores between groups demonstrated statistically worse outcomes for those who received corticosteroids as part of their initial treatment.

"Considering that no prior research has conclusively demonstrated benefit of corticosteroid therapy for any manifestation of Lyme disease, including neurologic, rheumatologic or cardiac manifestations, we urge strong caution in prescribing corticosteroids in cases where facial paralysis is clearly the result of acute Lyme disease until better evidence is available," said Dr. Jowett. "Appropriate antibiotic therapy should be promptly initiated in all cases."
-end-
In addition to Drs. Hadlock and Jowett, co-authors of the Laryngoscope report include Robert A. Gaudin, M.D., and Caroline A. Banks, M.D., of the Department of Otolaryngology at Massachusetts Eye and Ear and Harvard Medical School.

About Massachusetts Eye and Ear

Mass. Eye and Ear clinicians and scientists are driven by a mission to find cures for blindness, deafness and diseases of the head and neck. Now united with Schepens Eye Research Institute, Mass. Eye and Ear is the world's largest vision and hearing research center, developing new treatments and cures through discovery and innovation. Mass. Eye and Ear is a Harvard Medical School teaching hospital and trains future medical leaders in ophthalmology and otolaryngology, through residency as well as clinical and research fellowships. Internationally acclaimed since its founding in 1824, Mass. Eye and Ear employs full-time, board-certified physicians who offer high-quality and affordable specialty care that ranges from the routine to the very complex. In the 2016-2017 "Best Hospitals Survey," U.S. News & World Report ranked Mass. Eye and Ear no. 1 in the nation for ear, nose and throat care and #1 in New England for eye care. For more information about life-changing care and research, or to learn how you can help, please visit MassEyeAndEar.org.

Massachusetts Eye and Ear Infirmary

Related Lyme Disease Articles from Brightsurf:

Cracking the Lyme disease code
The next time a tick feeds on you, Washington State University researchers hope to make sure persistent arthritis caused by Lyme disease doesn't linger for a lifetime.

Many lyme disease cases go unreported; A new model could help change that
A new model based on 17 years of data can help predict the trajectory of where Lyme disease will spread.

Ethnobotanical medicine is effective against the bacterium causing Lyme disease
A preclinical in vitro study shows that selected plant-based herbal medicines, especially Ghanaian quinine and Japanese knotweed, work better than antibiotics against the bacterium that causes Lyme disease.

Paper-based test could diagnose Lyme disease at early stages
After a day hiking in the forest, the last thing a person wants to discover is a tick burrowing into their skin.

Lyme disease claim lines increased 117% from 2007 to 2018
From 2007 to 2018, claim lines with diagnoses of Lyme disease increased nationally 117%.

New effective vaccines for Lyme disease are coming
There is no effective vaccine currently available to prevent Lyme disease in humans.

New test diagnoses Lyme disease within 15 minutes
Current testing for Lyme disease, called the standard 2-tiered approach or the STT, involves running two complex assays (ELISA and western blot) to detect antibodies against the bacterium, and requires experienced personnel in a lab, and a few hours to carry out and interpret.

An innovative new diagnostic for Lyme disease
In new research, Joshua LaBaer, executive director of the Biodesign Institute at Arizona State University and his colleagues describe an early detection method for pinpointing molecular signatures of the disease with high accuracy.

Mouse, not just tick: New genome heralds change in Lyme disease fight
As Lyme disease increases, researchers have taken a significant step toward finding new ways to prevent its transmission.

Breakthrough paves way for new Lyme disease treatment
Virginia Tech biochemist Brandon Jutras has discovered the cellular component that contributes to Lyme arthritis, a debilitating and extremely painful condition that is the most common late stage symptom of Lyme disease.

Read More: Lyme Disease News and Lyme Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.